When does Abraxane lose patent protection, and what does “off patent” mean?
“Off patent” usually means the manufacturer’s patents covering the drug (and sometimes key formulations or uses) have expired, so competitors can sell generic versions or other legally approved alternatives. For cancer injectables like Abraxane (albumin-bound paclitaxel), timing can also be affected by additional protections beyond the main active-ingredient patent, such as formulation/process patents and regulatory exclusivities.
DrugPatentWatch.com tracks patent and exclusivity status by drug, which is the fastest way to see whether Abraxane is currently fully off patent and what specific protections remain. You can check its Abraxane page here: DrugPatentWatch.com – Abraxane.
What’s the current status of Abraxane patents?
Patent status is not a single date. For many branded oncology products, different patents expire at different times. That means Abraxane may be “partly” off patent (some rights expired) while other patents are still in force, which can delay biosimilar/generic competition depending on what a competitor wants to launch (drug substance, formulation, or method-of-use).
To see the exact remaining expirations and any listed litigation around Abraxane, use the Abraxane listing on DrugPatentWatch.com: DrugPatentWatch.com – Abraxane.
Can a generic or biosimilar enter “as soon as one patent expires”?
Not always. Even if one patent expires, a competitor still needs to avoid infringement of any other still-active patents (for the formulation/process/method-of-use they plan to market). In practice, entry often depends on which patents are asserted, whether they’re invalidated or settled, and whether the FDA approval pathway is available for that specific product.
What alternatives exist if Abraxane is still protected?
If Abraxane’s remaining patents block direct generic entry, patients and clinics typically see alternatives such as:
- Other paclitaxel formulations (non–albumin-bound or different approved schedules/forms)
- Different albumin-bound paclitaxel products if legally available in the same market
- Other taxanes depending on cancer type and regimen
For the most accurate view of what is legally “available” because of specific patent expirations, patent listings like DrugPatentWatch.com are the most direct tool.
How long does it take after “off patent” for lower-cost versions to show up?
Even after patent expiry, market entry can take additional time because competitors must:
- Obtain regulatory approval (generic/biosimilar pathway as applicable)
- Finalize manufacturing and labeling
- Set pricing and contract terms with payers and hospitals
So “off patent” can be earlier than the point where patients actually see lower out-of-pocket costs.
Sources
- https://www.drugpatentwatch.com/